In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease

References

• Bohan A, Peter JB. Polymyositis and dermatomyositis: Part 1 and 2. N Engl J Med 1975; 292: 344–347, 403–407
   PubMed Web of Science ®Google Scholar
• Wasicek CA, Reichlin M, Montes M, Raghu G. Polymyositis and interstitial lung disease in a patient with anti-Jo-1 prototype. Am J Med 1984; 76: 538–544
   PubMedGoogle Scholar
• Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23: 881–888
   PubMed Web of Science ®Google Scholar
• Mathews M, Bernstein R. Myositis auto-antibodies inhibit histidyl-tRNA synthetase: A model for auto-immunity. Nature 1983; 83: 304–317
   Google Scholar
• Margueire C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77: 1019–1038
   PubMedGoogle Scholar
• Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983; 26: 604–611
   PubMed Web of Science ®Google Scholar
• Masseau AI, Hamidou M, Agard C, Grolleau JY, Cherin P. Antisynthetase syndrome. J Bone Spine 2003; 70: 161–168
   PubMedGoogle Scholar
• Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614–622
   PubMed Web of Science ®Google Scholar
• Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroder DR, Ryu JH. Polymyositis–dermatomyositis associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182–1185
   PubMed Web of Science ®Google Scholar
• Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution tomography in early systemic sclerosis. J Rheumatol 1991; 18: 1520–1528
   PubMed Web of Science ®Google Scholar
• Diot E, Boissinot E, Asquier E, Guilmot JL, Lemarie E, Valat C, Diot P. Relationship between abnormalities on high-resolution CT and the pulmonary function in systemic sclerosis. Chest 1998; 114: 152028
   Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal Official Statement of the European Respiratory Society. Eur Respir J 1993; 6(Suppl. 16)5–40
   PubMed Web of Science ®Google Scholar
• Cotes JE, Chinn DJ, Quanjer PhH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Eur Respir J 1993; 6(Suppl. 16)41–52
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Kassan SS, Pillemer SR, Tala N, Weisman MH. Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American–European consensus group. Ann Rheum Dis 2002; 61: 544–548
   PubMed Web of Science ®Google Scholar
• Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis–dermatomyositis: A 20-year study of hospital diagnosed cases in Allegheny county, PA 1963–1982. J Rheumatol 1990; 17: 1329–1334
   PubMed Web of Science ®Google Scholar
• Medsger TA, Jr, Dawson WN, Jr, Masi AT. The epidemiology of polymyositis. Am J Rheumatol 1970; 48: 715–723
   Google Scholar
• Patrick M, Buckbinder R, Jolley D, et al. Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering. J Rheumatol 1999; 26: 1094–1100
   PubMed Web of Science ®Google Scholar
• Spath M, Schroder M, Schlotter-Weigel B, Walter MC, Hautmann H, Leinsinger G, Pongratz D, Muller-Felber W. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 2004; 251: 859–864
   PubMed Web of Science ®Google Scholar
• Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogenous patient group. Medicine (Baltimore) 1991; 70: 360–374
   PubMed Web of Science ®Google Scholar
• Reichlin M, Arnett FC, Jr. Multiplicity of autoantibodies in myositis sera. Arthritis Rheum 1984; 27: 1150–1156
   PubMed Web of Science ®Google Scholar
• Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to a small nuclear and cytoplasmic ribonucleoproteins in Japanes patients with inflammatory muscle disease. Arthritis Rheum 1992; 35: 449–456
   PubMed Web of Science ®Google Scholar
• Mimori T. Structures targeted by the immune system in myositis. Curr Opin Rheumatol 1996; 8: 521–527
   PubMedGoogle Scholar
• Targoff IN. Immune manifestations in inflammatory muscle disease. Rheum Dis Clin N Am 1994; 20: 857–880
   PubMed Web of Science ®Google Scholar
• Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller F, et al. Clinical, serological and immunogenetic features of polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1992; 40: 1257–1266
   Google Scholar
• Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. Autoimmunity 2005; 38: 73–78
   PubMed Web of Science ®Google Scholar
• Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, Martìnez-Gomez X, Majò-Masferrer J, Solans-Laque R, Simeon-Aznar CP, Morell-Brotard F, Vilardel-Tarres M. Polymyositis/dermatomyositis-associated lung disease: Analysis of a series of 81 patients. Lupus 2005; 14: 534–542
   PubMed Web of Science ®Google Scholar
• Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63: 297–301
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614–622
   PubMed Web of Science ®Google Scholar
• Targoff IN, Miller FW, Medsger TA, Jr, Oddis CV. Classification criteria for the inflammatory myopathies. Curr Opin Rheumatol 1997; 9: 527–535
   PubMedGoogle Scholar
• Greenwald R, Tashkin DP, Gong H, et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Am J Med 1987; 83: 83–92
   PubMedGoogle Scholar
• Steen V, Conte C, Owens GR, et al. Severe restrictive disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283–1289
   PubMedGoogle Scholar
• Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97–99, [editorial]
   PubMedGoogle Scholar